
Fiona Simpkins, MD, discusses the utility of cyclin E1 protein expression as a biomarker to predict response to azenosertib in ovarian cancer.

Your AI-Trained Oncology Knowledge Connection!


Fiona Simpkins, MD, is the Hilarie L. and Mitchell L. Morgan President’s Distinguished Professor in Women’s Health at the University of Pennsylvania Perelman School of Medicine in Philadelphia; an attending physician of Gynecologic Oncology in the Department of Ob/Gyn in the Hospital of the University of Pennsylvania; director of Clinical & Translational Gynecologic Oncology Research at the Penn Medicine Health System; and active staff of Gynecologic Oncology in the Department of Ob/Gyn at Chester County Hospital.

Fiona Simpkins, MD, discusses the utility of cyclin E1 protein expression as a biomarker to predict response to azenosertib in ovarian cancer.

Fiona Simpkins, MD, discusses key findings from the phase 2 DENALI trial evaluating azenosertib in patients with platinum-resistant ovarian cancer.